Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

Transcription

1 Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description (Cosentyx ) is a human interleukin-17a antagonist. FDA Approved Indication(s) Cosentyx is indicated for the treatment of: Moderate to severe plaque psoriasis () in adult patients who are candidates for systemic therapy or phototherapy Adults with active psoriatic arthritis () Adults with active ankylosing spondylitis (AS) Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions that Cosentyx is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Plaque Psoriasis (must meet all): 1. Diagnosis of moderate-to-severe ; 2. Prescribed by or in consultation with a dermatologist or rheumatologist; 4. Member meets one of the following (a or b): a. Failure of a trial of methotrexate (MTX) at up to a dose of mg/week used for 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced; b. If intolerance or contraindication to MTX, failure of a trial of cyclosporine or acitretin unless contraindicated or clinically significant adverse 6. Dose does not exceed 300 mg at weeks 0, 1, 2, 3 and 4, then every 4 weeks thereafter. B. Ankylosing Spondylitis (must meet all): 1. Diagnosis of active AS; 2. Prescribed by or in consultation with a rheumatologist; 4. Failure of at least two non-steroidal anti-inflammatory drugs (NSAIDs), each tried for at least 1 month at maximal recommended or tolerated anti-inflammatory doses, unless contraindicated or clinically significant adverse 6. Dose does not exceed 150 mg at weeks 0, 1, 2, 3, and 4 (loading dosage), then every 4 weeks thereafter. Page 1 of 5

2 C. Psoriatic Arthritis (must meet all): 1. Diagnosis of active ; 2. Prescribed by or in consultation with a dermatologist or rheumatologist; 4. Member meets one of the following (a or b): a. Failure of a trial of MTX for 3 consecutive months unless contraindicated or clinically significant adverse effects are experience; b. If intolerance or contraindication to MTX, failure of a trial of leflunomide, sulfasalazine, cyclosporine used for 3 consecutive months, unless contraindicated or clinically significant adverse 6. Dose does not exceed 150 mg at weeks 0, 1, 2, 3 and 4 (loading dosage), then 300 mg every 4 weeks thereafter. D. Other diagnoses/indications 1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). II. Continued Therapy A. All Indications in Section I (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria; 2. Member is responding positively to therapy (e.g., labs, sign/symptom reduction, no disease progression, no significant toxicity); 3. If request is for a dose increase, new dose does not exceed the following: a. For : 300 mg every 4 weeks; b. For AS: 150 mg every 4 weeks; c. For : 300 mg every 4 weeks. Approval duration: 12 months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy. Approval duration: Duration of request or 6 months (whichever is less); or 2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). III. Diagnoses/Indications for which coverage is NOT authorized: A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy ERX.PA.01 or evidence of coverage documents. IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key AS: ankylosing spondylitis : psoriatic arthritis FDA: Food and Drug Administration : plaque psoriasis Appendix B: Therapeutic Alternatives Page 2 of 5

3 Drug Name Dosing Regimen Dose Limit/ Maximum Dose cyclosporine (Sandimmune Neoral ) mg/kg/day PO divided BID 4 mg/kg/day methotrexate (Rheumatrex ) acitretin (Soriatane ) sulfasalazine (Azulfidine ) leflunomide (Arava ) NSAIDs (indomethacin, ibuprofen, naproxen, celecoxib, meclofenate, etc.) adalimumab (Humira, Amjevita )* etanercept (Enbrel, Erelzi )* mg/kg/day 10 to 25 mg/week, IM, IV or PO 7.5 to 15 mg/week PO 25 or 50 mg PO daily 2,000 mg/day PO 100 mg/day PO loading dose for 3 days followed by 20 mg/day PO AS Varies 80 mg SC initial dose, followed by 40 mg SC every other week starting one week after initial dose AS, 40 mg SC every other week. AS 50 mg SC once weekly 25 mg SC twice weekly or 50 mg SC once weekly 30 mg/week PO 50 mg/day PO 5 gm/day 100 mg/day Varies 40 mg SC every other week as maintenance 50 mg once weekly as maintenance 50 mg SC twice weekly for 3 months followed by 50 mg SC once weekly Therapeutic alternatives are listed as Brand name (generic) when the drug is available by brand name only and generic (Brand name ) when the drug is available by both brand and generic. *Requires PA V. Dosage and Administration Indication Dosing Regimen Maximum Dose 300 mg SC at week 0, 1, 2, 3, and 4 followed by 300 mg 300 mg every 4 weeks every 4 weeks (for some patients, a dose of 150 mg may be acceptable) 150 mg SC at week 0, 1, 2, 3, and 4 followed by 150 mg 300 mg every 4 weeks every 4 weeks; if a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg AS Loading dose: 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without loading dose: 150 mg every 4 weeks 150 mg every 4 weeks Page 3 of 5

4 VI. Product Availability Single-use Sensoready pen: 150 mg/ml Single-use prefilled syringe: 150 mg/ml Lyophilized powder in a single-use vial: 150 mg VII. References 1. Cosentyx Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January Available at Accessed October 2, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KM, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol Sep;61(3): Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May;58(5): Reviews, Revisions, and Approvals Date P&T Approval Date Policy created For all trial/failure requirements, indicated that member can also meet criteria if intolerant (as opposed to just contraindicated) to therapy in question. Modified the following initial criteria sets: -: indicated that disease must be moderate to severe. -AS: indicated that disease must be active. -: indicated that disease must be active. Modified trial/failure requirement- instead of requiring 2 or more nonbiologic DMARDs (such as cyclosporine, sulfasalazine, azathioprine, hydoxychloroquine), criteria now requires MTX; if MTX is contraindicated, then cyclosporine, sulfasalazine, leflunomide, cyclosporine, or azathioprine may be trialed. 4Q17 Annual Review -Converted to new template. -For all indications: Diagnostic criteria modified to require verifiable information; Specified trial of conventional and biologic DMARDs for 3 months or greater; provided alternatives if intolerance or contraindication to MTX -AS: removed trial of another biologic per TCR; -: removed requirement for trial of phototherapy and topical therapy Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. Page 4 of 5

5 This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein. Page 5 of 5